# Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

> **NCT04506619** · — · TERMINATED · sponsor: **Oak Hill Bio Ltd** · enrollment: 26 (actual)

## Conditions studied

- Retinopathy of Prematurity (ROP)
- Intraventricular Hemorrhage
- Bronchopulmonary Dysplasia
- Chronic Lung Disease of Prematurity

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04506619
- **Lead sponsor:** Oak Hill Bio Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-09
- **Primary completion:** 2022-08-05
- **Final completion:** 2022-08-05
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** As the revised OHB-607-202 protocol extends the study's observational arm through 24 months corrective age (CA), the SHP607-203 protocol was terminated at 24 months CA.
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04506619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04506619, "Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04506619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*